Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Jeff Settleman
Cracking the Code of Cancer from the Inside Out
Every advance against cancer reveals the same truth: this is a disease that has “learned” to fight back. There are more than 200 types of cancer, and the biology of a tumor is constantly changing. Block one pathway of cell growth and the cancer cells will find another, making resistance a common challenge in cancer treatment. Scientists continue to explore new options to circumvent cancer’s escape tactics.
Thinking Differently about Cancer Treatment Regimens
Perspective Jeff Settleman, João M. Fernandes Neto and René Bernards DOI: 10.1158/2159-8290.CD-20-1187 Published May 2021 Abstract Summary: Most experimental cancer drugs ultimately fail during the course of clinical development, contributing to the high cost of the few that are granted regulatory approval. Moreover, approved drugs often deliver only modest clinical benefit to patients with advanced disease due to the development of resistance.
Emerging Trends in Cancer Drug Discovery-From Drugging the “Undruggable” to Overcoming Resistance
Perspective Joachim Rudolph, Jeff Settleman and Shiva Malek DOI: 10.1158/2159-8290.CD-21-0260 Published April 2021 This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below. Abstract Summary: Technology advancement and the courage to challenge dogma have been key elements that have continuously shifted druggability limits.
A Single-Step, High-Dose Selection Scheme Reveals Distinct Mechanisms of Acquired Resistance to Oncogenic Kinase Inhibition in Cancer Cells
Translational Science Kenneth J. Finn, Scott E. Martin and Jeff Settleman DOI: 10.1158/0008-5472.CAN-19-0729 Published January 2020 This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below. Abstract Despite the remarkable clinical efficacy demonstrated by molecularly targeted cancer therapeutics, the benefits are typically temporary due to the emergence of acquired drug resistance.
A Single-Step, High-Dose Selection Scheme Reveals Distinct Mechanisms of Acquired Resistance to Oncogenic Kinase Inhibition in Cancer Cells
Translational Science Kenneth J. Finn, Scott E. Martin and Jeff Settleman DOI: 10.1158/0008-5472.CAN-19-0729 Abstract Despite the remarkable clinical efficacy demonstrated by molecularly targeted cancer therapeutics, the benefits are typically temporary due to the emergence of acquired drug resistance. This has spurred a massive effort by the cancer research community to identify mechanisms used by cancer cells to evade treatment.
A single-step, high-dose selection scheme reveals distinct mechanisms of acquired resistance to oncogenic kinase inhibition in cancer cells
Research Article Kenneth J Finn, Scott E Martin and Jeff Settleman DOI: 10.1158/0008-5472.CAN-19-0729 Abstract Despite the remarkable clinical efficacy demonstrated by molecularly-targeted cancer therapeutics, the benefits are typically temporary due to the emergence of acquired drug resistance. This has spurred a massive effort by the cancer research community to identify mechanisms used by cancer cells to evade treatment.
Jeff Settleman, Ph.D., Joins Pfizer to Lead Oncology Research & Development - Odessa American: Business
NEW YORK--(BUSINESS WIRE)--Jun 5, 2019-- Pfizer Inc. (NYSE: PFE) announced today that Jeff Settleman, Ph.D., will join the company as Senior Vice President and Group Head of Oncology Research & Development, leading all early oncology research, from discovery to proof of concept clinical studies.
Communication in Drug Development: “Translating” Scientific Discovery
FiguresFigure 1Communication Challenges Associated with the Process of Drug DevelopmentOn the left, the various steps involved in a typical drug development program are described, beginning with the early discovery and reporting of candidate therapeutic targets or pharmacologic agents and culminating with regulatory drug approval and clinical implementation.
Communication in Drug Development: “Translating” Scientific Discovery
FiguresFigure 1Communication Challenges Associated with the Process of Drug DevelopmentOn the left, the various steps involved in a typical drug development program are described, beginning with the early discovery and reporting of candidate therapeutic targets or pharmacologic agents and culminating with regulatory drug approval and clinical implementation.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Jeff
Contact Jeff, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack